You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

The Afternoon Show in Gynecologic Oncology: The Evolution of Cervical Cancer

  • Authors: Bradley J. Monk, MD, FACOG, FACS; Krishnansu S. Tewari, MD; Shannon N. Westin, MD, MPH, FACOG
  • CME / ABIM MOC Released: 4/6/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 4/6/2023
Start Activity


Target Audience and Goal Statement

This activity is intended for oncology specialists, obstetrics/gynecologists, nurse practitioners, and physician assistants.

The goal of this activity is that learners will be better able to improve oncologists and other healthcare provider (HCP) knowledge and increase confidence regarding current and emerging therapeutic options in advanced cervical cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Use of molecular testing to identify treatment options in advanced cervical cancer
    • Clinical trial data on novel therapies for the management of advanced cervical cancer
  • Have greater competence related to
    • Implementing novel therapies for eligible patients with advanced cervical cancer
    • Mitigating treatment-related adverse events for patients receiving novel therapies in advanced cervical cancer
  • Demonstrate greater confidence in their ability to
    • Identify the optimal uses of novel therapies for patients with advanced cervical cancer


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Bradley J. Monk, MD, FACS, FACOG

    Professor
    Division of Gynecologic Oncology
    University of Arizona College of Medicine
    Creighton University School of Medicine
    Director, Principal Investigator, Community Research Development
    HonorHealth Research Institute
    Phoenix, Arizona

    Disclosures

    Served as an advisor or consultant for: Agenus; Akeso Bio; Aravive; AstraZeneca; Clovis Oncology; Eisai; Elevar; EMD Merck; Genentech; Genmab; GlaxoSmithKline; Gradalis; ImmunoGen; Karyopharm; Iovance; Merck; Mersana; Myriad; Novocure; Pfizer; Puma; Regeneron; Roche; Seagen Inc. formerly Seattle Genetics, Inc.; Sorrento; Tesaro; US Oncology Research; VBL Therapeutics
    Served as a speaker or a member of a speakers bureau for: AstraZeneca; Clovis Oncology; Eisai; Genentech; GlaxoSmithKline; Merck; Roche; Tesaro

  • Krishnansu S. Tewari, MD

    Professor
    Division of Gynecologic Oncology, Obstetrics & Gynecology
    Director
    Fellowship Program, Division of Gynecologic Oncology, Obstetrics & Gynecology
    The Philip J. DiSaia, MD, Chair
    Gynecologic Oncology, Obstetrics & Gynecology
    School of Medicine
    University of California, Irvine
    Irvine, California

    Disclosures

    Disclosure: Krishnansu S. Tewari, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; AstraZeneca; Clovis Oncology; Eisai; Genentech; GlaxoSmithKline; Merck; Regeneron; Roche; Tesaro
    Served as a speaker or a member of a speakers bureau for: AstraZeneca; Clovis Oncology; Eisai; Merck; Roche
    Received grants for clinical research from: AbbVie; AstraZeneca; Genentech; Merck; Regeneron; Roche

  • Shannon N. Westin, MD, MPH, FACOG

    Associate Professor 
    Department of Gynecologic Oncology and Reproductive Medicine
    Division of Surgery
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Disclosure: Shannon N. Westin, MD, MPH, FACOG, has the following relevant financial relationships:
    Served as an advisor or consultant for: Agenus; AstraZeneca; Clovis Oncology; Eisai; EQRx; Genentech; GlaxoSmithKline; ImmunoGen; Lilly; Merck; Mereo; Novartis; Pfizer; Roche; Vincerx; Zentalis
    Received grants for clinical research from: AstraZeneca; Bayer; Bio-Path; Clovis Oncology; Genentech; GlaxoSmithKline; Mereo; Novartis; OncXerna; Roche; Zentalis

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC 

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships. 

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

The Afternoon Show in Gynecologic Oncology: The Evolution of Cervical Cancer

Authors: Bradley J. Monk, MD, FACOG, FACS; Krishnansu S. Tewari, MD; Shannon N. Westin, MD, MPH, FACOGFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 4/6/2022

Valid for credit through: 4/6/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to improve oncologists and other healthcare provider (HCP) knowledge and increase confidence regarding current and emerging therapeutic options in advanced cervical cancer.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print